CLDN3 and familial pancreatic carcinoma: The binding ability of CPE to claudins, especially claudin-3 and claudin-4, has raised a great opportunity to target cancers with dysregulated claudin-3 and -4 cancers, especially breast, ovarian, and pancreatic cancers.